Amgen Inc. v. Strides Pharma Global PTE Limited
1:16-cv-00881
Overview
Parties
Defendant
Strides Pharma Inc. Operating Company
Represented By
2 Attorneys ListedSeitz, Van Ogtrop & Green, P.A.
Seitz, Van Ogtrop & Green, P.A., 222 Delaware Avenue, Suite 1500
Seitz, Van Ogtrop & Green, P.A.
Seitz, Van Ogtrop & Green, P.A., 222 Delaware Avenue, Suite 1500
Strides Pharma Global PTE Limited NPE (University / Research)
Represented By
5 Attorneys ListedSeitz, Van Ogtrop & Green, P.A.
Seitz, Van Ogtrop & Green, P.A., 222 Delaware Avenue, Suite 1500
Seitz, Van Ogtrop & Green, P.A.
Seitz, Van Ogtrop & Green, P.A., 222 Delaware Avenue, Suite 1500
Amgen Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 8 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 9,375,405 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2016033897 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2018024323 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2019011759 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2020022234 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2021005251 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 50,221,903 P | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 7,829,595 B2 | US Continuation / Sibling | View Official Patent → |
Complex Innovations, LLC v. Amgen Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9375405
Rapid dissolution formulation of a calcium receptor-active compound
|
Filed: 2010-11-09
Issued: 2016-06-28
|
Active (1.1 yrs remaining)
Expires: 2027-12-14
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
5
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings